Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab
Evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy.